Constellation Pharmaceuticals Inc. [NASDAQ: CNST] slipped around 0.0 points on Thursday, while shares priced at $33.63 at the close of the session, down 0.00%. The company report on June 11, 2021 that SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates DSSI, FMBI, CNST, SLCT; Shareholders are Encouraged to Contact the Firm.
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Diamond S Shipping Inc. (NYSE:DSSI)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to International Seaways, Inc. Under the merger agreement, Diamond S shareholders will receive 0.55375 shares of International Seaways common stock for each share of Diamond S common stock held.If you are a Diamond S shareholder, click here to learn more about your rights and options.
Constellation Pharmaceuticals Inc. stock is now 16.77% up from its year-to-date (YTD) trading value. CNST Stock saw the intraday high of $33.70 and lowest of $33.59 per share. The company’s 52-week high price is 40.84, which means current price is +78.69% above from all time high which was touched on 01/20/21.
Compared to the average trading volume of 1.25M shares, CNST reached a trading volume of 2215830 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Constellation Pharmaceuticals Inc. [CNST]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CNST shares is $47.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CNST stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Constellation Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 04, 2021. The new note on the price target was released on June 03, 2021, representing the official price target for Constellation Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $50, while BMO Capital Markets analysts kept a Outperform rating on CNST stock.
The Average True Range (ATR) for Constellation Pharmaceuticals Inc. is set at 1.32 The Price to Book ratio for the last quarter was 4.26, with the Price to Cash per share for the same quarter was set at 7.98.
How has CNST stock performed recently?
Constellation Pharmaceuticals Inc. [CNST] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.62. With this latest performance, CNST shares gained by 64.05% in over the last four-week period, additionally plugging by 12.40% over the last 6 months – not to mention a drop of -3.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNST stock in for the last two-week period is set at 82.76, with the RSI for the last a single of trading hit 89.02, and the three-weeks RSI is set at 75.88 for Constellation Pharmaceuticals Inc. [CNST]. The present Moving Average for the last 50 days of trading for this stock 23.12, while it was recorded at 33.69 for the last single week of trading, and 25.69 for the last 200 days.
Constellation Pharmaceuticals Inc. [CNST]: Deeper insight into the fundamentals
Return on Total Capital for CNST is now -31.47, given the latest momentum, and Return on Invested Capital for the company is -32.10. Return on Equity for this stock declined to -33.77, with Return on Assets sitting at -30.05. When it comes to the capital structure of this company, Constellation Pharmaceuticals Inc. [CNST] has a Total Debt to Total Equity ratio set at 1.03. Additionally, CNST Total Debt to Total Capital is recorded at 1.02, with Total Debt to Total Assets ending up at 0.96. Long-Term Debt to Equity for the company is recorded at 0.14, with the Long-Term Debt to Total Capital now at 0.14.
Reflecting on the efficiency of the workforce at the company, Constellation Pharmaceuticals Inc. [CNST] managed to generate an average of -$820,500 per employee.Constellation Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.40 and a Current Ratio set at 15.40.
Earnings analysis for Constellation Pharmaceuticals Inc. [CNST]
With the latest financial reports released by the company, Constellation Pharmaceuticals Inc. posted -0.7/share EPS, while the average EPS was predicted by analysts to be reported at -0.63/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNST.
Insider trade positions for Constellation Pharmaceuticals Inc. [CNST]
There are presently around $1,951 million, in the hands of institutional investors. The top three institutional holders of CNST stocks are: SVENNILSON PETER with ownership of 6,051,376, which is approximately 0% of the company’s market cap and around 1.53% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 4,404,129 shares of the stock with an approximate value of $148.11 million in CNST stocks shares; and VR ADVISER, LLC, currently with $135.09 million in CNST stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Constellation Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 64 institutional holders increased their position in Constellation Pharmaceuticals Inc. [NASDAQ:CNST] by around 4,343,687 shares. Additionally, 61 investors decreased positions by around 3,096,729 shares, while 24 investors held positions by with 50,565,888 shares. The mentioned changes placed institutional holdings at 58,006,304 shares, according to the latest SEC report filing. CNST stock had 14 new institutional investments in for a total of 777,115 shares, while 18 institutional investors sold positions of 739,513 shares during the same period.